1,436 results on '"Riemekasten, G"'
Search Results
52. POS1203 INCREASED PROTEASE-ACTIVATED RECEPTOR 1 AUTOANTIBODIES ARE ASSOCIATED WITH SEVERE COVID-19
53. POS0872 SERUM LEVEL OF SOLUBLE INTERLEUKIN-2 RECEPTOR IS LINKED TO BETA2-MICROGLOBULINE, NT-PRO BNP AND HIGH-SENSITIVITY TROPONIN T AND MAY HELP TO IDENTIFY PATIENTS WITH EARLY CLINICAL PROGRESS IN SSc.
54. POS0471 INDUCED ANTIBODIES DIRECTED TO THE ANGIOTENSIN RECEPTOR TYPE 1 PROVOKE SKIN AND LUNG INFLAMMATION AND DERMAL FIBROSIS AND ACT SPECIES OVERARCHING
55. POS0474 ACTIVATION AND HYPERSENSITIZATION OF THE ANGIOTENSIN II TYPE 1 AND ENDOTHELIN-1 TYPE A RECEPTORS BY AGONISTIC AUTOANTIBODIES CONTRIBUTES TO VASCULAR INJURY IN SCLERODERMA RENAL CRISIS
56. OP0158 COHORT ENRICHMENT STRATEGIES FOR PROGRESSIVE INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS FROM EUSTAR
57. Extrazelluläre Vesikel und Autoantikörper aus Serum von Patient:innen mit systemischer Sklerose als Mediatoren der Aktivierung von Monozyten
58. Systemic sclerosis with ANCA or rare overlap of three diseases? A case report
59. Serum levels of soluble interleukin-2 receptor correlate with beta2-microglobulin, NT-pro BNP and high-sensitivity troponin T and may help to identify patients with clinical progress in SSc
60. Clustering model of 23 antibodies against G protein-coupled receptors (GPCR) identifies two different subsets of ANCA-associated vasculitis (AAV) with different prognosis
61. Sera of patients with systemic sclerosis contain molecular components which damage the glycocalyx of human umbilical vein endothelial cells
62. IgG derived from systemic sclerosis and giant cell arteritis patients evokes a different cytokine response of THP-1 cells than healthy control IgG
63. Gemeinsame deutschsprachige Nomenklatur für die systemische Sklerose
64. Regulatorische T-Zellen und rheumatische Erkrankungen
65. IL-2- Therapie beim SLE – Selektive Rekonstitution immunologischer Toleranz
66. Efficacité du nintédanib chez des patients présentant une pneumopathie interstitielle diffuse associée à la sclérodermie systémique (PID-ScS) avec atteinte des organes internes : données de l’étude SENSCIS
67. Geschlechtsspezifische Unterschiede des Immunsystems
68. The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodies
69. Dying neutrophils contribute to the granulomatous inflammation by interaction with high-mobility group box 1 and IL-33 in granulomatosis with polyangiitis: 6.62
70. Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database
71. P.06 - Causes et facteurs prédictifs de mortalité dans la sclérodermie systémique : une analyse à partir de 3 700 décès
72. Retrospective comparison of drug treatment of joint involvement in systemic sclerosis: 6.18
73. IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS.
74. OP0266 EFFICACY OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) AND INTERNAL ORGAN INVOLVEMENT: DATA FROM THE SENSCIS TRIAL
75. POS1449 SEGMENTED SHORT-FORMAT ONLINE EDUCATION SIGNIFICANTLY INCREASES PREDICTION, PROGNOSIS, AND MANAGEMENT OF FIBROSING INTERSTITIAL LUNG DISEASE ASSOCIATED WITH CONNECTIVE TISSUE DISEASE
76. OP0054 NEW ROLE FOR PROTEINASE 3 IN IL-16 BIOACTIVITY CONTROL IN GRANULOMATOSIS WITH POLYANGIITIS
77. POS0834 LONG-TERM OUTCOME OF SSC ASSOCIATED ILD: IMPROVED SURVIVAL IN PPI TREATED PATIENTS
78. POS0335 THE POTENTIAL ROLE OF IL13 IN VASCULOPATHY IN SYSTEMIC SCLEROSIS PATIENTS
79. OP0244 28 NEW AUTOANTIBODIES AGAINST GPCR, GROWTH FACTORS AND GROWTH FACTOR RECEPTORS ARE ASSOCIATED WITH DISEASE MANIFESTATIONS IN SYSTEMIC SCLEROSIS
80. POS0318 CLINICAL PHENOTYPE IN SCLERODERMA PATIENTS WITH ANTI-TOPOISOMERASE I POSITIVITY AND LIMITED CUTANEOUS FORM: DATA FROM THE EUSTAR DATABASE
81. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
82. Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database
83. A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc
84. CLINICAL PHENOTYPE IN SCLERODERMA PATIENTS WITH ANTI-TOPOISOMERASE I POSITIVITY AND LIMITED CUTANEOUS FORM: DATA FROM THE EUSTAR DATABASE
85. LONG-TERM OUTCOME OF SSC ASSOCIATED ILD: IMPROVED SURVIVAL IN PPI TREATED PATIENTS
86. A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc
87. Anti-ADRB2 antibodies in systemic sclerosis affect the inflammatory cytokine response of immune cells
88. Rapid detection of functional human cytomegalovirus-specific CD8+ T cells via integrin activation
89. Kritische Extremitätenischämie bei systemischer Sklerose
90. The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis
91. Studentenprogramm 2013: Ein Rückblick
92. Implementation von Leitlinien für eine Therapie der systemischen Sklerose (Sklerodermie): Wunsch und Wirklichkeit
93. FRAGMENTS OF AT1R AND ETAR-ANTIBODIES INDUCE COMPLEMENT-INDEPENDENT ENDOTHELIAL ACTIVATION: P089
94. STRUCTURAL AND FUNCTIONAL BASIS OF ANGIOTENSIN II AND PATHOGENIC IGG MEDIATED AT1R ACTIVATION: V09
95. Autoantibodies against the Thrombin receptor (PAR-1) are substantially reduced in patients with heart failure: results from the CIBIS-ELD trial: 1184
96. Organspezifische Diagnostik von Patienten mit systemischer Sklerodermie: Empfehlungen des Deutschen Netzwerkes für Systemische Sklerodermie (DNSS)
97. Risikoadaptierte Therapien bei der systemischen Sklerose
98. 30-jährige Patientin mit plötzlich aufgetretenen hämorrhagischen Nekrosen beider Beine
99. Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study
100. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.